small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (657)
  • Capabilities (81)
  • Experience (154)
  • Insights & News (5,780)
  • Other Results (89)

Professionals 657 results

Mats G. Carlston
Mats G. Carlston
Partner
  • New York
Email
+1 212-294-6696
vCard

Partner

  • New York
Krishnan Padmanabhan
Krishnan Padmanabhan
Partner
  • New York, 
  • Los Angeles, 
  • Silicon Valley
Email
+1 212-294-3564
vCard

Partner

  • New York
  • Los Angeles
  • Silicon Valley
Reid Smith
Reid Smith
Partner
  • Chicago
Email
+1 312-558-7241
vCard

Partner

  • Chicago
View All Professionals

Capabilities 81 results

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Industry

Financial Crimes Compliance

Winston’s financial crimes compliance lawyers have been providing regulatory compliance counseling and enforcement services related to the Bank Secrecy Act (BSA), the Anti-Money Laundering Act of 2020 (AML), and countering the financing of terrorism (CFT) policy for decades. We also have experience with international AML matters, including in the EU and with respect to Financial Actions Task Force (FATF) recommendations....Read more

Industry

Artificial Intelligence (AI)

Experience 154 results

Experience

|

June 12, 2025

Winston Serves as Lead Counsel to CGP Capital Partners in New Continuation Vehicle

Experience

|

May 2, 2025

Copley Acquisition Corp. Closes $172.5 Million Initial Public Offering

Experience

|

April 30, 2025

Federal Circuit Backs PayPal

View All Experience

Insights & News 5,780 results

Webinar

|

July 17, 2025

Newly Public Companies: How to Thrive After Ringing the Bell

Going public is a major milestone, but it is only the beginning. Newly public companies must quickly adapt to a dynamic environment defined by regulatory obligations, market scrutiny, and constant stakeholder expectations. Join us for a timely webinar as our panel of industry leaders explores how companies can successfully navigate life after the IPO....Read more

Capital Markets & Securities Law Watch

|

June 30, 2025

|

7 Min Read

Recent Executive Orders Are Reshaping DEI Disclosures in 2025 Proxy Statements

Following a series of executive orders issued by the Trump administration targeting DEI initiatives, many companies have made significant changes to their proxy statements this season. Disclosures relating to racial and gender diversity were once considered essential, and while proxy advisory firms continue to consider such disclosures when making voting recommendations, now many companies are skirting around the topic or eliminating any mention of diversity altogether. 

Pro Bono In Action

|

June 27, 2025

|

1 Min Read

Winston and Accenture Secure Asylum for Honduran who Fled to the U.S. After a Gang Killed his Family

In partnership with our commercial client Accenture, Winston lawyers helped secure asylum for a pro bono client who fled Honduras after a vicious gang massacred six members of his family because his father would not hand over their land....Read more
View All Insights & News

Other Results 89 results

Law Glossary

What Is the Standard for the FDA to Grant a Generic Drug License?

An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug....Read more

Law Glossary

What Is the Approval Process for Generic Drugs?

Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug....Read more

Law Glossary

What Is a Generic Drug?

Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising